Renate Degrave - Biocartis Group Head Communications

All Insiders . Belgium . 
Stock . Biocartis Group NV . Stakeholders . Insider . Renate Degrave
BCART Stock  EUR 0.29  0.00  0.00%   

Insider

Renate Degrave is Head Communications of Biocartis Group NV
Phone32 1 563 20 00
Webhttps://www.biocartis.com

Biocartis Group Management Efficiency

The company has return on total asset (ROA) of (0.2245) % which means that it has lost $0.2245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (48.8364) %, meaning that it generated substantial loss on money invested by shareholders. Biocartis Group's management efficiency ratios could be used to measure how well Biocartis Group manages its routine affairs as well as how well it operates its assets and liabilities.
Biocartis Group NV has accumulated 128.15 M in total debt with debt to equity ratio (D/E) of 40.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biocartis Group NV has a current ratio of 2.76, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biocartis Group until it has trouble settling it off, either with new capital or with free cash flow. So, Biocartis Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biocartis Group NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biocartis to invest in growth at high rates of return. When we think about Biocartis Group's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Arjen MScArgen X
38
An PhanCelyad SA
N/A
Philippe NobelsCelyad SA
57
Marina UdierBlagovicCelyad SA
N/A
Maria KoehlerCelyad SA
62
Karl GubitzArgen X
53
Hannes IserentantCelyad SA
N/A
BME MBACelyad SA
66
Filip BorgionsArgen X
N/A
EMBA MBAArgen X
50
Stephen RubinoCelyad SA
N/A
Gustavo PazOntex Group NV
61
Jonas DerooOntex Group NV
N/A
Dominic PiscitelliCelyad SA
N/A
Gaelle VilatteOntex Group NV
N/A
MD MBChBCelyad SA
57
David GeorgesCelyad SA
N/A
Sara ZelkovicCelyad SA
N/A
Keith WoodsArgen X
55
David MDArgen X
71
Laurent NiellyOntex Group NV
N/A
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. The company was founded in 2007 and is headquartered in Mechelen, Belgium. BIOCARTIS operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. It employs 619 people. Biocartis Group NV (BCART) is traded on Euronext Brussels in Belgium and employs 619 people.

Management Performance

Return On Equity-48.84
Return On Asset-0.22

Biocartis Group NV Leadership Team

Elected by the shareholders, the Biocartis Group's board of directors comprises two types of representatives: Biocartis Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biocartis. The board's role is to monitor Biocartis Group's management team and ensure that shareholders' interests are well served. Biocartis Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biocartis Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
Reginald Genechten, Head Chain
Benoit Devogelaere, Chief Officer
Erwin Sablon, Head Management
Geert Maertens, Chairman Officer
JeanMarc Roelandt, Chief Officer
Piet Houwen, Chief Officer
Renate Degrave, Head Communications
Herman Verrelst, CEO Director
Dirk Zimmermann, Global Partnering
Susy Spruyt, Head Organization

Biocartis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biocartis Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-48.84
Return On Asset-0.22
Profit Margin(1.07) %
Operating Margin(0.85) %
Current Valuation182.31 M
Shares Outstanding93.1 M
Shares Owned By Insiders6.66 %
Shares Owned By Institutions27.71 %
Price To Earning(9.91) X
Price To Book6.47 X

Other Information on Investing in Biocartis Stock

Biocartis Group financial ratios help investors to determine whether Biocartis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biocartis with respect to the benefits of owning Biocartis Group security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY